Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8237 in HDM-Induced Allergic Rhinitis
NCT01700192Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Jan 2013
- Primary completion
- Apr 2015
- Modality
- Allergy Immunotherapy
01
Overview
A Phase 3 trial of House dust mite allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by ALK-Abelló. Started Jan 2013; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01700192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01700192.